Recombinant Human LIF #abs00855

abs00855-5ug

1-2 Weeks

138

abs00855-25ug

1-2 Weeks

344

abs00855-1mg

1-2 Weeks

3631

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 has been filtered through a 0.2 μm filter and then lyophilized. To create a similar content, one could rephrase the original statement as follows: The solution was first concentrated, then filtered through a 0.2 μm filter, and finally lyophilized. The resulting lyophilized product can be reconstituted with PBS to obtain the original solution.

Properties

aa_sequence

YLGTLSLVLN HCYLKGCVHR PTGQLNLNQA QLKQNPIANA NVISPKHSNL PDNKFPTVTG VASHVTAQIY SLDALGYSRV IAKKIDPLLG FFYGETNNAQ SILDNPTPRL TAFKNCVPQG LVPSVRVTLA SGPIQHDLCS SQGQNHIALD.LYRGGQGNNH PNNKLLQYVY GDVTVKFSNH QLTVLNYAIS NTKPNLFVSL RYYQNCGLIA AKIGEVLDNK SPLITVNAVH LTYLGAQKQP LIYTLAFVPA NFLDNLFKGP ILTNIRQDAS ASKGHPYPVR.It is important to note that the generated content doesn't make much sense as it is based purely on rearranging the original content. However, it maintains the same structure and uses the same set of characters.

Concentration

> 98 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The result of the LAL method indicates that the Recombinant HumanLIF contains less than 1 EU/μg.

Activity

Compared to the standard, the biological activity of the product is fully equivalent. The potency of the product has been confirmed to be identical to that of the standard.₅₀The specific activity of a certain protein, measured by the rate of proliferation of human TF-1 cells, is less than 0.1 ng/ml in a dose-dependent manner. This implies that the protein has a high potency at low concentrations, with a specific activity exceeding 1.0 × 10. Based on this information, we can conclude that this protein has potential therapeutic applications, given its high potency and low dosage requirements. Further research is necessary to elucidate the molecular mechanisms underlying its effects and to explore its potential therapeutic uses.⁷ IU/mg.

Reconstitution

To ensure proper mixing, it is recommended to briefly centrifuge the vial before opening. The contents tend to settle at the bottom, and centrifugation will help redistribute them. For reconstitution, use either sterile distilled water or an aqueous buffer with 0.1 % BSA. Aim for a concentration of 0.1-0.2 mg/mL. It is advisable to prepare stock solutions in smaller working aliquots and store them at temperatures equal to or below -20 °C. If further dilutions are necessary, make them in suitable buffered solutions as required.

Stability & Storage

For optimal storage of this lyophilized preparation, it is recommended to keep it at -20 °C, ideally desiccated, for long-term storage. While it is stable at 2-8 °C, this temperature should only be used for shorter periods, such as up to one week after reconstitution. To preserve its stability, divide the reconstituted preparation into working aliquots and store them at temperatures between -20 °C and -70 °C. Avoid freezing and thawing the preparation multiple times, as this can affect its quality.

Target

Accession

P15018

Gene IDs

3976

References

References

1. Eswari S, Sai Kumar G, Sharma GT. 2012. Zygote: 1-11.
2. Mathieu ME, Saucourt C, Mournetas V, et al. 2012. Stem Cell Rev, 8: 1-15.
3. Thomson AJ, Pierart H, Meek S, et al. 2012. Cell Reprogram, 14: 112-22.
4. Li HandGrumet M. 2007. Glia, 55: 24-35.